1-2 of 2
Vishnu Peddagali
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

John O. Mascarenhas, Raajit Rampal, Firas El Chaer, Vikas Gupta, Kazuya Shimoda, Jean-Jacques Kiladjian, Francesco Passamonti, Prithviraj Bose, Joseph M. Scandura, Ruben Mesa, Lindsay A.M. Rein, Junichiro Yuda, David M Ross, Timothy Devos, Moshe Talpaz, Ronald Hoffman, Sujan Kabir, Zhonggai Li, Jason M. Foulks, Karen Ansaldo, Masataka Seki, Vishnu Peddagali, Jatin Shah, Claire Harrison
Journal: Blood
Blood (2024) 144 (Supplement 1): 6629.
https://doi.org/10.1182/blood-2024-200268
Published: 2024
Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Lindsay A.M Rein, Firas El Chaer, Junichiro Yuda, Kazuya Shimoda, James McCloskey, Akiyoshi Takami, Tamanna Haque, Michiko Ichii, Shuichi Shirane, Masafumi Fukaya, Joseph M. Scandura, Terrence Bradley, Pankit Vachhani, Takayuki Tabayashi, Steven Green, Stanley Cheung, Prithviraj Bose, Sharad Khurana, Casey L. O'Connell, Idoroenyi Amanam, David M. Ross, Sujan Kabir, Masataka Seki, Mark Wade, Vishnu Peddagali, Zhonggai Li, Jatin Shah, Raajit K. Rampal
Journal: Blood
Blood (2023) 142 (Supplement 1): 626.
https://doi.org/10.1182/blood-2023-180164
Published: 2023